Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Eur Acad Dermatol Venereol ; 35(10): 2079-2084, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33988879

RESUMO

BACKGROUND: Maculopapular cutaneous mastocytosis (MPCM) in children is classified in two variants: (i) monomorphic variant, presenting with the small macules or papules typically seen in adult patients; and (ii) polymorphic variant with larger lesions of variable size and shape, typically seen in children. The definition of polymorphic and monomorphic variants is mostly intuitive, and a validation of this classification has not been done. OBJECTIVE: To study interobserver variability in the classification of MPCM in two groups of observers: mastocytosis experts and general dermatologists. MATERIALS AND METHODS: Nineteen cases of childhood MPCM were shown blindly, for classification as monomorphic or polymorphic type, to 10 independent observers (eight dermatologists, one allergist and one haematologist) from Europe and North America with a vast experience in the management of paediatric mastocytosis. Also, the same cases were shown on a screen to 129 general dermatologists attending a meeting; their votes were registered by remote controls. The interobserver variability kappa coefficient (with 95% confidence interval) was calculated to measure the reliability of the correlation. RESULTS: The value of kappa interobserver variability coefficient for the group of 10 experts (95% confidence interval) was 0.39 (0.18-0.63), which is considered as 'fair'. The value of kappa interobserver variability coefficient for the group of 129 general dermatologists (95% confidence interval) was 0.17 (0.06-0.39), which is considered as 'slight'. A complete agreement of all 10 experts was achieved in only four of 19 cases (21.1%) The most voted choice was concordant between the two groups in only 11 of the 19 cases. CONCLUSIONS: We failed to validate the classification system of childhood MPCM in monomorphic and polymorphic types. While the rate of agreement was low for mastocytosis experts, it was nearly the agreement expected by chance in general dermatologists.


Assuntos
Urticaria Pigmentosa , Adulto , Criança , Europa (Continente) , Humanos , Variações Dependentes do Observador , Reprodutibilidade dos Testes
3.
J Eur Acad Dermatol Venereol ; 34(1): 161-165, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31423677

RESUMO

BACKGROUND: Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering disease. Patients occasionally present with a clinical picture of pruritus/urticaria alone for months and do not even develop blisters over time. Only few studies have investigated this subgroup of non-bullous pemphigoid (NBP). OBJECTIVE: To evaluate the demographic and clinical characteristics of BP patients with or without blisters at the time of diagnosis. METHODS: A retrospective study based on the medical records of 115 BP patients. Collected data included demographic characteristics, clinical presentation, treatment and response to treatment. RESULTS: Thirty-six patients presented with pruritus/urticaria (31.3%), and 79 presented with blisters (68.7%), with mean ages of 77.5 and 76.0, respectively, at diagnosis and an equal female:male ratio. The level of immunoglobulin E (IgE) was 4.1 times higher, and the mean blood eosinophil count was significantly increased in the pruritus/urticaria group. Remission rate at 3 months and relapse rate were similar between the groups. Median follow-up period was 9 months (range 3-18). Only 23% of the patients with pruritus/urticaria developed blisters. CONCLUSIONS: A significant number of BP patients present without blisters. We found no significant epidemiological or clinical differences from the classic BP patients aside from significantly elevated IgE and blood eosinophil levels. Similar results in larger cohort studies might be the foundation for a change in clinical protocols regarding the diagnosis and recommended treatment for the elderly presenting with pruritus/urticaria only.


Assuntos
Penfigoide Bolhoso/complicações , Penfigoide Bolhoso/diagnóstico , Idoso , Idoso de 80 Anos ou mais , Vesícula/sangue , Vesícula/diagnóstico , Vesícula/etiologia , Eosinófilos , Feminino , Humanos , Imunoglobulina E/sangue , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Penfigoide Bolhoso/terapia , Prurido/sangue , Prurido/diagnóstico , Prurido/etiologia , Estudos Retrospectivos , Avaliação de Sintomas , Urticária/sangue , Urticária/diagnóstico , Urticária/etiologia
4.
J Eur Acad Dermatol Venereol ; 30(7): 1171-5, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26347371

RESUMO

BACKGROUND: Cutaneous leishmaniasis (CL) due to Leishmania major (L. major) is common in the Middle East; however, this skin infection may be under-diagnosed when it presents atypically. OBJECTIVE: To highlight the occurrence of uncommon presentations of CL that may elude diagnosis. MATERIALS AND METHODS: A retrospective study was performed among patients who presented at The Sheba Medical Center between 2005 and 2014 with atypical clinical presentations of CL due to L. major. RESULTS: Twelve patients with unusual clinical presentations of L. major CL were identified. All infections were acquired in L. major - endemic areas of Israel. The average age was 37 years. The average number of lesions was 2. Nine patients presented with a form that mimicked other forms of CL, such as lupoid, giant ulcer, sporotrichoid and recidivans, and three had a variant resembling other infectious skin diseases, such as erysipeloid and verruciform. All patients required systemic therapy. CONCLUSION: Cutaneous leishmaniasis due to L. major can masquerade as many other infectious and inflammatory diseases. In addition, it can mimic clinical forms of New World CL. We suggest that in endemic countries or in travellers returning from countries where L. major is endemic, polymerase chain reaction (PCR) for Leishmania-specific DNA should be performed routinely in cases of unusual presentations of dermatitis with a single or a few lesions, even if a diagnosis of CL was not considered by the referring clinician.


Assuntos
Leishmania major/patogenicidade , Leishmaniose Cutânea/diagnóstico , Adulto , Feminino , Humanos , Leishmaniose Cutânea/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto Jovem
6.
Br J Dermatol ; 171(5): 1078-83, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24673403

RESUMO

BACKGROUND: Onchocerciasis is an infectious disease caused by the filaria Onchocerca volvulus. Very little is known regarding onchocerciasis imported from endemic to nonendemic areas. OBJECTIVES: To evaluate pruritic dermatitis simulating atopic dermatitis in Ethiopian immigrants in Israel. PATIENTS AND METHODS: A retrospective study of 27 Ethiopian immigrants to Israel was conducted. Demographics and clinical and laboratory data were collected. RESULTS: Of the group of 27 patients, 10 (37%) were men and 17 (63%) were women. The average age at referral was 29 years. All of the patients emigrated from Kuwara, Ethiopia. Diagnosis was done by either positive skin snip test or immunoglobulin (Ig) G4 serology of onchocerciasis in 14 patients. The most common presentation was a combination of lichenified onchodermatitis with atrophy and depigmentation (36%). Eosinophilia and elevated IgE levels were common. Seventeen patients were treated with a single administration of oral ivermectin 200 µg mg(-1). Thirteen patients responded to the treatment. CONCLUSIONS: Immigrants from endemic regions to developed countries presenting with pruritic diseases, especially those with a clinical picture suggestive of atopic dermatitis, should be evaluated for possible onchocerciasis infection. Ivermectin, a relatively safe and low-cost treatment, should be considered even in the absence of a proven disease. Physicians should have a high index of suspicion in patients with the corresponding residential history.


Assuntos
Emigrantes e Imigrantes , Oncocercose/etnologia , Adolescente , Adulto , Antiparasitários/uso terapêutico , Criança , Dermatite Atópica/etnologia , Dermatite Atópica/parasitologia , Etiópia/etnologia , Feminino , Humanos , Israel/epidemiologia , Ivermectina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Oncocercose/tratamento farmacológico , Prurido/etnologia , Prurido/parasitologia , Estudos Retrospectivos , Adulto Jovem
7.
Br J Dermatol ; 169(1): 12-9, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23668474

RESUMO

Haemangioma is a vascular tumour of infancy that is well known for its rapid growth during the first weeks to months of a child's life, followed by a spontaneous but slow involution. During the proliferative phase, the vessels are disorganized and composed of immature endothelial cells. When the tumour involutes, the vessels mature and enlarge but are reduced in number. Fat, fibroblasts and connective tissue replace the vascular tissue, with few, large, feeding and draining vessels evident. Both angiogenesis and vasculogenesis have been proposed as mechanisms contributing to the neovascularization in haemangioma tumours. In recent years, several of the 'building blocks', the cells comprising the haemangioma, have been isolated. Among them are haemangioma progenitor/stem cells, endothelial cells and pericytes. This review focuses on these cell types, and the molecular pathways within these cells that have been implicated in driving the pathogenesis of infantile haemangioma.


Assuntos
Hemangioma/etiologia , Neoplasias Cutâneas/etiologia , Corticosteroides/uso terapêutico , Antagonistas Adrenérgicos beta/uso terapêutico , Angiopoietinas/fisiologia , Células-Tronco Embrionárias/patologia , Endotélio Vascular/patologia , Hemangioma/tratamento farmacológico , Hemangioma/patologia , Humanos , Lactente , Mastócitos/patologia , Propranolol/uso terapêutico , Receptor TIE-2/fisiologia , Receptores Notch/fisiologia , Receptores de Fatores de Crescimento do Endotélio Vascular/fisiologia , Transdução de Sinais/fisiologia , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/patologia , Serina-Treonina Quinases TOR/fisiologia , Fator A de Crescimento do Endotélio Vascular/fisiologia
9.
Pathobiology ; 75(6): 346-55, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-19096230

RESUMO

BACKGROUND: One strategy to increase tissue specificity of gene therapy is to use promoters or enhancers. OBJECTIVES: (1) To enhance the selectivity of a murine preproendothelin-1 (PPE-1) promoter in tumor angiogenesis by using a positive endothelial transcription-binding element. (2) To test the specificity and efficiency of the modified PPE-1 promoter [PPE-1(3X)] in vitro and in vivo by using reporter genes, and the therapeutic gene herpes simplex virus-thymidine kinase (HSV-TK) in a mouse model of Lewis lung carcinoma (LLC). RESULTS: The modified PPE-1 promoter specifically induced expression in the tumor angiogenic vascular bed with a 35-fold higher expression compared to the normal vasculare bed of the lung. Thus, when the HSV-TK gene controlled by the modified PPE-1 promoter was used systemically, it induced tumor-specific necrosis, apoptosis and mononuclear infiltrates, leading to massive destruction of the neovasculature of the pulmonary metastasis, which suppressed metastasis development. CONCLUSIONS: These results show that an adenoviral vector armed with HSV-TK controlled by the endothelial-selective murine PPE-1(3X) promoter is efficient and safe to target tumor neovasculature.


Assuntos
Carcinoma Pulmonar de Lewis/terapia , Endotelina-1/genética , Terapia Genética/métodos , Neovascularização Patológica/terapia , Regiões Promotoras Genéticas , Simplexvirus/enzimologia , Timidina Quinase/genética , Adenoviridae/genética , Animais , Carcinoma Pulmonar de Lewis/irrigação sanguínea , Endotélio Vascular/metabolismo , Genes Virais/genética , Vetores Genéticos , Pulmão/irrigação sanguínea , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Simplexvirus/genética , Timidina Quinase/metabolismo
10.
Cancer Gene Ther ; 15(8): 535-42, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18421310

RESUMO

Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrated that Ad-PPE-Fas-c induced Fas-receptor-mediated endothelial cell apoptosis. Previously, doxorubicin was shown to enhance Fas-receptor clustering and the induction of its cascade. Therefore, the goal of this work was to test whether doxorubicin augments the capacity of Ad-PPE-Fas-c to induce endothelial cell apoptosis and to elucidate whether either the death-receptor-mediated apoptotic cascade or the mitochondria-associated apoptotic cascade is involved in the combined treatment effect. We found that a combined treatment of Ad-PPE-Fas-c and doxorubicin synergistically induced a reduction in endothelial cell viability and apoptosis. z-IETD-FMK, a caspase-8 inhibitor, and z-LEHD-FMK, a caspase-9 inhibitor, significantly decreased apoptosis induced by the combined treatment. Systemically administered combined therapy significantly reduced the lung metastases burden (70%) in mice as compared to each treatment alone. Thus, a combined treatment of Ad-PPE-Fas-c gene therapy and chemotherapy may be effective in the treatment of metastatic diseases and both the Fas cascade and the mitochondria-associated cascade are essential for this effect.


Assuntos
Apoptose/efeitos dos fármacos , Caspase 8/metabolismo , Caspase 9/metabolismo , Doxorrubicina/administração & dosagem , Endotélio Vascular/efeitos dos fármacos , Terapia Genética , Metástase Neoplásica/prevenção & controle , Neovascularização Patológica/prevenção & controle , Adenoviridae/genética , Animais , Bovinos , Células Cultivadas , Endotélio Vascular/citologia , Vetores Genéticos , Camundongos , Camundongos Endogâmicos C57BL
11.
J Eur Acad Dermatol Venereol ; 22(3): 283-9, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18269595

RESUMO

BACKGROUND: Currently, psoriasis is thought to be an inflammatory response to an antigenic stimulation, in which angiogenesis plays a fundamental role. Very late antigen-1 (VLA-1) is a beta(1) integrin collagen receptor that is up-regulated in many angiogenic processes. Data on its role in psoriasis are sparse. OBJECTIVE: In a prospective study, we evaluated the staining of VLA-1 in lesional skin from patients with psoriasis and atopic dermatitis. MATERIAL AND METHODS: Frozen sections from skin biopsies of patients with chronic plaque-type psoriasis (n = 18) and chronic atopic dermatitis (n = 7) were stained with a monoclonal antibody to VLA-1. The number of blood vessels stained with VLA-1 and the staining intensity were evaluated. These were correlated with the histologic features. RESULTS: The absolute number of blood vessels was found to be similar in the atopic and psoriatic samples. However, the number of vessels stained with anti-VLA-1, as well as the staining intensity, was shown to be significantly higher in the psoriasis group (P < 0.05). Differences between psoriatic lesions showing typical histological features of psoriasis and those showing features that overlap with dermatitis were found as well. CONCLUSIONS: Expression of VLA-1 was found significantly higher in lesional dermal blood vessels of psoriatic patients compared with atopic patients. These findings suggest a possible role for VLA-1 in the pathological angiogenesis of psoriasis. It may be an additional tool for establishing the diagnosis of psoriasis and provide a basis for new strategies in the treatment of psoriasis.


Assuntos
Dermatite Atópica/metabolismo , Integrina alfa1beta1/metabolismo , Psoríase/metabolismo , Adulto , Idoso , Biópsia , Vasos Sanguíneos/metabolismo , Vasos Sanguíneos/patologia , Dermatite Atópica/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neovascularização Patológica/metabolismo , Neovascularização Patológica/patologia , Estudos Prospectivos , Psoríase/patologia , Pele/irrigação sanguínea , Pele/patologia , Células Th2/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...